The company says AFTX-201 is designed for cardiac transduction at 5- to 10-fold lower doses than conventional capsids, with preclinical studies in a disease model cited as restoring cardiac function.
“Over the past year, we have made tremendous progress…” Rick Modi says, as Affinia Therapeutics pushes its BAG3-DCM program toward first-in-human testing, aiming to prove that next-generation capsids can restore heart function at dramatically lower doses.
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.
